Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
5.13
+0.03 (0.59%)
At close: Oct 2, 2026, 4:00 PM EDT
5.20
+0.07 (1.36%)
After-hours: Oct 2, 2026, 7:30 PM EDT
Atea Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
411.45M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 351.37M | 302.73M | 622.49% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
AVIR News
- 18 days ago - Atea Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 25 days ago - Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Atea Pharmaceuticals price target raised to $7 from $6 at Morgan Stanley - TheFly
- 7 weeks ago - Atea Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 7 weeks ago - Atea Pharmaceuticals Earnings release: Q2 2026 - Filings
- 7 weeks ago - Atea Pharmaceuticals Slides: Q2 2026 - Filings
- 7 weeks ago - Atea Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 7 weeks ago - Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire